Masivet

RSS

masitinib mesilate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 26/09/2013

Authorisation details

Product details
Name
Masivet
Agency product number
EMEA/V/C/000128
Active substance
Masitinib mesilate
International non-proprietary name (INN) or common name
masitinib mesilate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QL01XE90
Publication details
Marketing-authorisation holder
AB Science S.A.
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
17/11/2008
Contact address
3 avenue George V
75008 Paris
France

Product information

24/09/2013 Masivet - EMEA/V/C/000128 - R/0016

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-KIT tyrosine-kinase receptor.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating